What is uMed?
uMed operates at the intersection of healthtech and clinical research, providing a modular suite of services designed to streamline the evidence generation process. The company specializes in decentralized study services, including patient recruitment and comprehensive data collection, which are essential for modernizing traditional clinical trial workflows. By prioritizing security, compliance, and patient trust, uMed enables healthcare professionals and pharmaceutical organizations to access diverse patient cohorts, thereby facilitating faster and more representative medical research. Its market position is defined by its commitment to enhancing the quality of life science data while maintaining the integrity of the patient journey.
How much funding has uMed raised?
uMed has raised a total of $12.4M across 1 funding round:
Other Financing Round
$12.4M
Other Financing Round (2023): $12.4M with participation from Delin Ventures, Playfair Capital, 11.2 Capital, and Albion Ventures
Key Investors in uMed
Delin Ventures
Delin Ventures is a mission-driven investor focused on transforming lives through innovations in life sciences and technology, providing operational expertise and long-term support to founders.
Playfair Capital
Playfair Capital is a London-based venture firm specializing in early-stage investments, known for its high graduation rate and commitment to helping startups become global category leaders.
11.2 Capital
11.2 Capital is a San Francisco-based venture capital firm that focuses on high-growth sectors including artificial intelligence, cybersecurity, and robotics.
What's next for uMed?
With this latest round of financing, uMed is poised to transition into a phase of aggressive scaling and product enhancement. The strategic focus will likely center on expanding its decentralized study platform to accommodate larger, more complex global trials. By leveraging the expertise of its high-profile investor base, the company is well-positioned to refine its technological stack, potentially integrating advanced analytics to further optimize patient recruitment and retention. As the industry shifts toward more patient-centric research models, uMed's ability to maintain its competitive edge will depend on its continued commitment to operational excellence and its capacity to navigate the regulatory complexities inherent in the life sciences sector.
See full uMed company page
